Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.33 |
| ▸ | GRM8 | O00222 | 3/20 | 0.33 |
| ▸ | GRM6 | O15303 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731152 | 1.00 | MEN1 (0.34) | MEN1KMT2APPARDGRM4GRM8 | |
| SCHEMBL751482 | 0.81 | MEN1 (0.36) | MEN1KMT2ATSHRTP53TDP1 | |
| SCHEMBL733018 | 0.81 | MEN1 (0.36) | MEN1KMT2ATSHRTP53TDP1 | |
| SCHEMBL3513000 | 0.79 | GRM4 (0.37) | GRM4GRM8GRM6TSHR | |
| SCHEMBL751484 | 0.77 | GRM4 (0.36) | GRM4GRM8GRM6 | |
| SCHEMBL731005 | 0.77 | GRM4 (0.36) | GRM4GRM8GRM6 | |
| SCHEMBL751704 | 0.76 | GRM4 (0.35) | GRM4GRM8GRM6 | |
| SCHEMBL731196 | 0.76 | GRM4 (0.35) | GRM4GRM8GRM6 | |
| SCHEMBL14008504 | 0.75 | MEN1 (0.32) | MEN1KMT2APPARD | |
| SCHEMBL752528 | 0.75 | MEN1 (0.32) | MEN1KMT2APPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377873-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8138164-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100317623-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100298210-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317623-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | MEN1 4761/4885KMT2A 3629/4885PPARD 3119/4885 |
| US-20100298210-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | MEN1 4767/4885KMT2A 3688/4885PPARD 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.